Debra K. Liebert - 11 Jul 2025 Form 4 Insider Report for Milestone Pharmaceuticals Inc. (MIST)

Role
Director
Signature
/s/ Jason Minio, Attorney-in-Fact
Issuer symbol
MIST
Transactions as of
11 Jul 2025
Net transactions value
$0
Form type
4
Filing time
15 Jul 2025, 16:15:28 UTC
Previous filing
09 Jun 2023
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Liebert Debra K. Director C/O MILESTONE PHARMACEUTICALS INC., 1111 DR. FREDERIK-PHILIPS BLVD, STE 420, MONTR?AL, QUEBEC, CANADA /s/ Jason Minio, Attorney-in-Fact 15 Jul 2025 0001772891

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MIST Common Shares Award +16,666 +13123% 16,793 11 Jul 2025 Direct F1
holding MIST Common Shares 10,000 11 Jul 2025 By: The Rodriguez and Liebert Revocable Trust
holding MIST Common Shares 4,000 11 Jul 2025 By: Trust F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MIST Series A Common Warrants (right to buy) Award +16,793 16,793 11 Jul 2025 Common Shares 16,793 $1.50 Direct F1, F3
transaction MIST Series B Common Warrants (right to buy) Award +16,793 16,793 11 Jul 2025 Common Shares 16,793 $1.88 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported securities are included within 16,793 Issuer Units purchased by the Reporting Person for $1.50 per Unit. Each Unit consists of one common share, one Series A common warrant and one Series B common warrant, each warrant represents the right to purchase 16,793 shares of common stock.
F2 These shares are held in a trust for the benefit of several including the Reporting Person's spouse. The Reporting Person's spouse is a co-executor of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
F3 Fully vested and exercisable.